Our Consultants and Partners have excellent academic backgrounds in biomedical and/or economic sciences combined with entrepreneurial spirit and extensive experience in world-leading health science companies. Target BioScience AG adheres strictly to the highest ethical standards and integrates client know-how.
Dr. Meinrad Good
Meinrad Good is founder and Managing Director of Target BioScience AG. He has extensive knowledge and experience in the pharmaceutical industry sector and has performed a number of consulting projects on a national and international level in scientific and regulatory affairs, quality assurance and business development. Meinrad Good has a PhD degree in Biochemistry and an advanced degree in General Management, both from the University of Zurich.
Dr. Maria Heimgartner
Maria Heimgartner has joined Target BioScience AG as a senior consultant in 2012 and serves now as a Principal Consultant in quality assurance, market access and business development. Prior to joining Target BioScience Maria Heimgartner has served as a General Manager for Genzyme Switzerland, a global biopharmaceutical company focused on rare diseases and multiple sclerosis. Maria Heimgartner brings over 15 years of pharmaceutical industry experience. Maria Heimgartner holds PhD degree from University of Munich and Bachelor of Science degree from University of Houston, Texas.
Dr. Jürgen Regenold
Jürgen Regenold has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of the global regulatory affair company Dr. Regenold GmbH as well as the founder of global regulatory group regulanet®. Jürgen Regenold manages all aspects of the business from strategic product development to regulatory affairs and market access. Previously he served in management of pharmaceutical product development and regulatory affairs. Jürgen Regenold holds a PhD degree as a pharmacist from the Albert-Ludwigs-University of Freiburg.
Dr. Patrik Frei
Patrik Frei has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of Venture Valuation AG, Switzerland. Since then he has been involved in over 350 valuations for investors as well as biotech, Pharma and medtech companies. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company and a board member of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik Frei graduated from the Business University of St. Gallen and completed his PhD thesis at the Swiss Federal Institute of Technology in Lausanne.
Dr. Stefan Maeser
Stefan Maeser serves as a Consultant since 2015. He has extensive knowledge and experiences in the life science industry. His core expertise lies within orphan drug, in particular in market evaluations, identification of key opinion leaders, organization of advisory boards meetings, programs for the diagnosis of symptomatic patients suffering from rare diseases. Prior to working as Consultant, Stefan Maeser has served as CEO and member of the supervisory board in the life science industry. Stefan Maesar studied biochemistry at the Free University of Berlin and business administration at the Berlin School of Economics and Law.
Monika Lenzer serves as a Consultant in regulatory affairs and as a responsible person for quality management in Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP). She has broad experiences as a practical pharmacist since 2004 and as consultant for regulatory affairs since 2007. Monika Lenzer holds a Master degree as a pharmacist from the Ludwigs-Maximillian-University in Munich.